The action of bromoconduritol on ER glucosidase II.
Yoichi Takeda, Kiichiro Totani, Ichiro Matsuo, Yukishige Ito
Index: Bioorg. Med. Chem. Lett. 20 , 5357-9, (2010)
Full Text: HTML
Abstract
Bromoconduritol (6-bromo-3,4,5-trihydroxycyclohex-1-ene; BCD) has been known as an inhibitor of glucosidase II (G-II), which plays pivotal roles in glycoprotein processing and folding in the ER. Previous works suggested that BCD specifically inhibits the cleavage of the innermost glucose (Glc) among two alpha1-3 linked Glc residues (cleavage-2). This study addressed the mode of BCD's inhibition toward G-II by using fluorescently labeled substrates. Our analysis clarified that BCD inhibits both cleavage-1 and cleavage-2 activities of G-II. However, the inhibitory activity toward cleavage-2 was 6-fold higher than that toward cleavage-1. Inhibition against both of these activities was retained after dialysis, supporting that BCD exhibits inhibition through irreversible binding to G-II.Copyright 2009. Published by Elsevier Ltd.
Related Compounds
Related Articles:
2015-08-28
[Biochem. Biophys. Res. Commun. 464 , 685-91, (2015)]
Evolution of polyphenols and organic acids during the fermentation of apple cider.
2014-11-01
[Biochem. J. 469(1) , 83-95, (2015)]
Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses.
2014-06-01
[Antimicrob. Agents Chemother. 58(6) , 3206-16, (2014)]
2009-01-01
[Microb. Cell Fact. 8 , 55, (2009)]
2008-06-25
[FEBS Lett. 582(15) , 2277-82, (2008)]